Salvo Health secures $8.5m Series A to advance gastrointestinal care
83% of Salvo patients are women. Its AI-enhanced, hybrid care model supports brick & mortar clinics to offer a continuous care platform.
Gastrointestinal care (GI) company Salvo Health has raised $8.5m in a Series A funding round as it looks to scale its hybrid, AI-enhanced model across the US, with a growing emphasis on conditions that disproportionately affect women.
The round was led by ManchesterStory, City Light Capital, and Threshold Ventures, with participation from new investors including The Artemis Fund, Contour Venture Partners, Owl Capital, and Impact X Capital Partners. Existing backers Human Ventures, Torch Capital, Felicis Ventures, and Alumni Ventures also took part. The raise brings Salvo’s total equity funding to $21.6m.
Additional layer for brick-and-mortar gastroenterogy practices
Salvo Health positions itself as an infrastructure layer for brick-and-mortar gastroenterology practices rather than a replacement for them. Its platform enables clinics to offer wraparound, multidisciplinary services in a continuous way — including nutrition, behavioural health, and nursing support — alongside traditional GI care, augmented by AI tools designed to improve efficiency and outcomes.
The company’s growth over the past year has been rapid. Salvo ended 2025 with patient and revenue growth of 800% year-on-year, while enterprise agreements with GI doctors grew by more than 1,000%.
It has signed agreements with 801 gastroenterologists, representing around 16% of all independent GIs in the US. Enterprise customers include three of the four largest GI practices in the country, together seeing more than 1.1 million patients annually across ten states.
83% of patients are women
While Salvo’s model is framed around GI care broadly, its patient demographics highlight how women have driven its rapid growth. According to the company, 83% of Salvo patients are women, reflecting the disproportionate burden of chronic GI conditions such as IBS, IBD, and obesity-related disorders among female patients.
“We see gut health as a missing ingredient in women’s health and mental health progress in this country,” said Katie Reiner Peykar, Partner at Torch Capital.
“83% of Salvo patients are women, reflecting the disproportionate impact of chronic GI burdens on women, and the legacy of stigma and gaslighting—especially around IBS and obesity care.”
Investors backing the round emphasised the role Salvo could play in expanding access to team-based GI care, particularly in underserved or community-based settings.
“We invested in Salvo to expand access to ‘whole person’ care to communities across the country where there can be a shortage of GI providers and obstacles to finding world-class multidisciplinary, team-based care,” said Matt Kinley, Founding Partner of ManchesterStory.
“Salvo is allowing community GI practices to build ‘Center of Excellence’ care for the 100 million Americans who suffer from chronic GI conditions such as IBD, IBS, GERD, celiac, and gastroparesis, as well as metabolic conditions such as MASLD and general obesity.”
The company’s approach has also attracted interest from investors focused on the responsible use of AI in healthcare.
“Salvo Health is winning because they chose to empower GI providers, not replace them,” said Diana Murakhovskaya, General Partner at The Artemis Fund. “With deep enterprise adoption, accelerating deployments, and a clear path to profitability, Salvo has emerged as the glue for modern multi-disciplinary GI care.
“We love that Salvo, like other leaders in the care economy, is treating AI as an accelerant, not the product. This round is about scaling a proven platform across one of healthcare’s largest and most underserved specialties.”
Outcomes data supports its approach
Salvo reports a growing body of outcomes data alongside its expansion. According to investors, 76% of patients report improved symptoms, and the company has seen a 79% reduction in GI-related emergency room utilisation among its patient population. Salvo has also had five abstracts on outcomes accepted and received a Blue Ribbon at the American College of Gastroenterology (ACG) annual meeting, with research showing symptom improvement alongside mental health gains for more than half of patients.
“The key with Salvo is patient-centered care,” said Eric Collins, Co-Founder and General Partner at Impact X Capital Partners.
“It’s critical to expand access to food as medicine and behavioral health to improve outcomes and lower long-term health care costs. Salvo does exactly that.”
Salvo’s founding leadership team—including CEO Jeffrey Glueck, COO Marin Rothenberg, and CMO Dr. Erin Hendriks— now plan to use the proceeds raised to expand Salvo’s engineering team with an AI-led roadmap and to increase national hiring of registered dieticians, behavioral health professionals, and nurses to meet rising patient demand.